Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A
Open Access
- 1 May 2018
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 11 (3) , 283-288
Abstract
An open-label, single-dose, randomized, two-period, crossover study comparing the pharmacokinetics of factor VIII activity in plasma (FVIII:C) after administration of an albumin-free presentation of moroctocog alfa (test) and moroctocog alfa manufactured using the previous technique (reference) was conducted in 30 (25 evaluable) male subjects who had severe hemophilia A (FVIII:C < 1 IU/dL). Blood samples were collected for 48 h after administration of each dose. FVIII:C was assayed using a chromogenic substrate assay. The FVIII:C pharmacokinetic parameters were calculated using noncompartmental analysis. The presentations would be bioequivalent if the 90% confidence limits of the ratio of the geometric mean values of AUC(inf) and recovery fell within the interval of 80-125%. The bioequivalence criteria were met. A total of 10 treatment-related adverse events were observed in a total of nine subjects. All were mild and none was determined to be related to administration of study medication.Keywords
Funding Information
- Pfizer
This publication has 14 references indexed in Scilit:
- Assessment of relative bioavailability of two presentations of moroctocog alfa (AF‐CC) in subjects with moderately severe or severe hemophilia AClinical Pharmacology in Drug Development, 2014
- Impact of being underweight or overweight on factor VIII dosing in hemophilia A patientsHaematologica, 2013
- Modern haemophilia careThe Lancet, 2012
- BDDrFVIII (Moroctocog alfa [AF‐CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal studyHaemophilia, 2010
- An improved manufacturing process for Xyntha/ReFacto AFHaemophilia, 2010
- Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIIIHaemophilia, 2009
- ReFacto®1 and Advate®2: a single‐dose, randomized, two‐period crossover pharmacokinetics study in subjects with haemophilia AHaemophilia, 2007
- In vivorecovery of factor VIII and factor IX: intra‐ and interindividual variance in a clinical settingHaemophilia, 2006
- B‐domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma‐derived factor VIII concentrate: a randomized, three‐way crossover studyHaemophilia, 2005
- A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.Proceedings of the National Academy of Sciences, 1986